R3i Global events
10 February 2023
Reducing Vascular Complications of Type 2 Diabetes:
New Targets, New Treatments
The R3i International Steering Committee meeting, Marrakech 2023
Marrakech, Morroco
1 September 2019
Addressing residual vascular risk :
Is a new therapy on the horizon?
R31 & IAS Press Conference
Paris, France
24 November 2018
The Selective Peroxisome Proliferator-Activated Receptor Alpha Modulator (SPPARMa) Concept
New Joint Initiative of the International Atherosclerosis Society (IAS) and Residual Risk Reduction Initiative (R3i) on the concept of SPPARM-a
Chantilly, France
13 June 2018
Highlights from the Joint Satellite Symposium of the IAS and the International Chair on Cardiometabolic Risk
IAS 2018 - XVIII International Symposium on Atherosclerosis
Toronto, Canada
26 August 2017
ESC 2017: New approaches to targeting residual cardiovascular risk
ESC Congress 2017
Barcelona, Spain
10 June 2017
MSDA 2017 - 12th Metabolic Syndrome, type II Diabetes and Atherosclerosis Congress
MSDA 2017 - 12th Metabolic Syndrome, type II Diabetes and Atherosclerosis Congress
Saint Petersburg, Russia
26 May 2015
ISA 2015 Coverage
The 17th International Symposium on Atherosclerosis
Amsterdam, The Nederlands
18 September 2014
Preventive cardiology R3i session
PEDIM 2014 - Prague European Days of Internal Medicine
Prague, Czech Republic
12 September 2014
MSDA Kyoto 2014 - A highlight of R3i activities
9th Metabolic syndrome, Type 2 Diabetes and Atherosclerosis Congress (MSDA 2014)
Kyoto, Japan
29 July 2014
CASMU R3i Symposium : Una actualización en dislipemias aterogénicas
La formación médica continua de la Escuela de Graduados, por encargo del Departamento de Cardiología de CASMU
Montevideo, Uruguay
22 March 2014
R3i Goes Global: Latin America launch at SOCESP
Sociedade de Cardiologia do Estado de Sao Paulo Congress (SOCESP 2014)
Sao Paulo, Brazil
4 October 2013
R3i symposium : Residual Risk – What does it mean? How to influence it?
12th European Congress of Internal Medicine
Prague, Czech Republic